X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 fusion protein. It is being evaluated in preclinical studies for the treatment of advanced pancreatic cancer.
Lead Product(s): Efineptakin Alfa
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
The collaboration aims to evaluate Imugene's allogeneic CAR T, azer-cel, in combination with NIT's proprietary immune T cell amplifier "Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.
Lead Product(s): Azercabtagene Zapreleucel,Efineptakin Alfa
Therapeutic Area: Oncology Product Name: Azer-Cel
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Imugene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 11, 2023
Details:
NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), is being developed for the treatment of Acute Radiation Syndrome and has shown potential in nonclinical studies to address the immunosuppressive effects of ARS.
Lead Product(s): Efineptakin Alfa
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NT-I7
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
NT-I7 (efineptakin alfa) (rhIL-7-hyFc) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.
Lead Product(s): Efineptakin Alfa
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NT-I7
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 03, 2023
Details:
Results showed the clinical efficacy of NT-I7 (efineptakin alfa) when combined with pembrolizumab in checkpoint-inhibitor-naïve microsatellite stable colorectal cancer (CPI-naïve MSS-CRC) and pancreatic cancer (CPI-naïve PaC).
Lead Product(s): Efineptakin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.
Lead Product(s): Efineptakin Alfa,Tisagenlecleucel
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit.
Lead Product(s): Efineptakin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
NT-I7 (efineptakin alfa) is a human IL-7 fusion protein that overcomes the key limitations of endogenous IL-7. The IL-7 domain promotes T cell development which plays a central role in immune response.
Lead Product(s): Efineptakin Alfa,Bevacizumab
Therapeutic Area: Oncology Product Name: NT-17
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
In the phase 1b/2a study NIT-106, the combination of NT-I7 (Efineptakin Alfa) with atezolizumab showed favorable safety and anticancer activity in CPI-relapsed/refractory high-risk skin cancer patients.
Lead Product(s): Efineptakin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
NT-I7 demonstrated in previous studies that it can increase number of memory T cells with prolonged effect, whereas IL-2activates effector T cell for a limited period, results of pre-clinical study showed that combination of their different MoAs created a anti-tumor response.
Lead Product(s): Efineptakin Alfa,Pembrolizumab
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
